Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB, _ _. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2019, 17: 459-468. PMID: 31085753, PMCID: PMC6712564, DOI: 10.6004/jnccn.2018.7109.Peer-Reviewed Original ResearchConceptsTesticular cancer survivorsPlatinum-based chemotherapyRisk factorsErectile dysfunctionCancer survivorsFirst-line platinum-based chemotherapyHealth outcomesMultivariable binary logistic regression analysisCisplatin-based chemotherapy regimenCardiovascular disease risk factorsVigorous-intensity physical activityPrevalence of hypogonadismTestosterone replacement therapyDisease risk factorsSerum testosterone levelsBody mass indexBinary logistic regression analysisYounger median ageAdverse health outcomesLogistic regression analysisYears of ageAnxiety/depressionGenetic risk factorsChemotherapy regimenSymptomatic patients